Real Madrid's struggles continue with 2-1 loss to Alaves    Egypt, South Sudan exchange viewpoints on support to implementation of peace agreement    New Egyptian league season to end in August; fan attendance not allowed    France's AFD, NBE sign €100 million credit facility agreement    Savills: Boom in global vaccine investment to benefit real estate investors in Middle East    Egypt's exported 4.8 mln tonnes of agriculture products in 11M: Minister    US aircraft carrier deploys to Gulf, Navy says unrelated to 'specific threats'    Ethiopian forces will take Tigrayan capital in coming days, military says    Experts: Virus numbers could be erratic after Thanksgiving    Match winner Afsha continues scoring habit to give Ahly Champions League title    Italy loosens COVID restrictions in five regions, including Lombardy    Egypt's Sisi inspects road projects under construction in Cairo    Light to heavy rainfall forecast in Egypt next week    Ethiopia to generate power from GERD in June 2021, says Ethiopian Minister    Cairo, Alexandria, Gharbiya and Luxor record highest coronavirus infection rates, minister    2021 Grammy Awards: List of nominees in top categories    Egypt's interior ministry takes legal action against 5,226 drivers, 483 shops for violating COVID-19 preventive measures    Sisi calls on citizens to closely observe COVID-19 preventive measures    UAE's ADGM to sign MOU with Israel's securities authority on fintech    Akhenaten performance at the Cairo Opera House is a must go    An advisory chamber    GERD: A point of order?    Leapfrogging the transport network    Cairo International Book Fair suspended for five months over coronavirus concerns    AstraZeneca novel COVID-19 vaccine can be 90% effective, results show    US will reduce number of its troop in Iraq, Afghanistan    Asia forms world's biggest trade bloc, a China-backed group excluding U.S    Egypt unveils largest archaeological discovery in 2020 with over 100 intact sarcophagi    Palestinians mourn the loss their longtime spokesman, Saeb Erekat    Trump says won't blame Egypt for being ‘upset' over GERD dispute with Ethiopia    1st stage of Egypt's parliamentary elections kicks off on Saturday    Global Finance: Egypt's Tarek Amer among the world's top 20 central bank governors    Legend footballer Lionel Messi says he is forced to stay with Barcelona    Egypt, Ethiopia, Sudan to resume Nile dam talks today    Iraqi conglomerate eyes developing land that housed Mubarak-era ruling party HQ    Legend Messi officially wants to leave Barcelona, hands transfer request    The Facebook Preacher's Search for Fame, and Egypt's Economy    Egypt calls on UNSC to address oil spill risks off Yemen coast    Egypt economically strong in face of COVID-19, reforms ongoing: International Cooperation Minister    Arafa Holding reports $144,000 COVID-19-related losses in April    Egypt's efforts in Libya to activate free will of Libyan people: Al-Sisi    Hyksos campaigns were internal takeover, not foreign invaders: study    COVID-19 affects Egypt sporting clubs    COVID-19 will soon turn to seasonal like swine flu: Presidential Health Advisor    ‘Egypt's Support' coalition convenes to discuss its Senate election list    Robbery attempt leads to discovery of Ptolemaic monuments in Qena    Flouting international guidance, Ethiopia unilaterally starts filling its Nile dam    Zaha speaks out after online racial abuse    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.





BioNTech, Pfizer testing potential coronavirus vaccine, could “supply millions” by year-end
Published in Amwal Al Ghad on 30 - 04 - 2020

German drugmaker BioNTech and U.S. pharmaceutical giant Pfizer have begun human trials of a potential coronavirus vaccine that could supply millions by the end of the year, the two firms said on Wednesday.
From its part, Pfizer said it would begin testing its experimental vaccine in the United States as early as next week, adding that a vaccine could be ready for emergency use in the fall, the Wall Street Journal reported on Tuesday.
BioNTech said the first cohort of participants had been given doses of the potential vaccine, BNT162, in a Phase 1/2 clinical study in Germany.
"Twelve study participants have been vaccinated with the vaccine candidate BNT162 in Germany since the start of the study on April 23, 2020,” the company said in a statement.
BioNTech said around 200 healthy volunteers aged between 18 to 55 years old would be given doses ranging from 1µg (microgram) to 100µg to find the optimal dose for further studies.
“In addition, the safety and immunogenicity of the vaccine will be investigated,” noted the German biotech company.
Pfizer and BioNTech plan to initiate trials for BNT162 in the U.S. on regulatory approval, expected shortly, the joint statement read.
The German Federal Institute for Vaccines and Biomedical Drugs has given the green light for the trial — the country's first clinical experiment for a vaccine against coronavirus on April 22.
“The two companies plan to jointly conduct clinical trials for the COVID-19 vaccine candidates initially in Europe and the U.S., across multiple research sites,” Pfizer announced in its first quarter report, released online on Tuesday.
“Pfizer and BioNTech also plan to conduct trials for BNT162 in the U.S. upon regulatory approval, which is expected shortly,” the report said.
“The companies estimate that there is potential to supply millions of vaccine doses by the end of 2020, subject to technical success of the development program and approval by regulatory authorities, and the potential to rapidly scale up the capacity to produce hundreds of millions of doses in 2021.”


Clic here to read the story from its source.